Form 4: Gossamer Bio COO/CFO Awarded Significant Equity

Gossamer Bio's COO/CFO, Bryan Giraudo, received significant equity awards, including restricted stock units and stock options, under a pre-arranged plan.

Summary

• Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., was granted 115,750 restricted stock units (RSUs) and options to purchase 693,750 shares of common stock.
• The RSU award has a vesting schedule of four equal annual installments, contingent on continuous service to the Issuer.
• The stock options have an exercise price of $2.88 per share and will vest 25% on January 2, 2027, with the remainder vesting monthly (1/48th) thereafter, also subject to continuous service.
• These transactions, dated January 2, 2026, were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Giraudo directly owns 389,737 shares of common stock and indirectly owns 480,010 shares via a family trust, in addition to the 693,750 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation in the form of equity awards, which is generally a positive sign of management alignment and retention. It's not a direct financial performance report, so the sentiment is based on corporate governance and incentive structure.

Positives

• Significant equity awards granted to a key executive (COO/CFO) demonstrate continued alignment of management's interests with shareholders.
• The awards are performance-based, tied to continuous service, incentivizing long-term commitment and performance.
• The transactions were made under a Rule 10b5-1 plan, indicating pre-planned and transparent equity compensation.

Negatives

• The awards are future-dated (January 2, 2026), meaning the immediate impact on beneficial ownership is for future vesting.
• The exercise price of the options ($2.88) provides a benchmark for future stock performance, but also means the options are only valuable if the stock price exceeds this.

Risks

• Future stock price performance could be below the option exercise price, rendering the options worthless.
• The vesting schedules are contingent on continuous service, meaning the executive would forfeit unvested awards upon departure.

Future Outlook

The equity awards are designed to incentivize the COO/CFO's long-term commitment and performance, with vesting schedules extending several years into the future, aligning executive interests with future company growth.

Industry Context

Equity compensation, particularly through RSUs and stock options with vesting schedules, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and motivate key executives, aligning their incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options for executive compensation is a common practice across the biotech and broader technology sectors, comparable to compensation structures seen at companies like Moderna, Biogen, or Gilead Sciences.
• Vesting schedules tied to continuous service are standard, ensuring executive retention and alignment with long-term company performance, similar to industry benchmarks.
• The exercise price of $2.88 for the options provides a clear performance hurdle, a common feature in incentive-based compensation plans.

Stakeholder Impact

• Shareholders: The awards align the COO/CFO's interests with shareholders by incentivizing long-term stock price appreciation and retention. Dilution from future option exercises or RSU vesting is a potential, but expected, impact.
• Employees: Demonstrates the company's approach to executive compensation, which can set a precedent or expectation for other employees' equity incentives.

Next Steps

• The restricted stock units will vest in four equal annual installments, subject to continuous service.
• 25% of the stock options will vest on January 2, 2027, with the remaining 1/48th vesting monthly thereafter, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting further fundamental updates.

Keywords

Gossamer Bio, GOSS, SEC Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Executive Compensation, Bryan Giraudo, COO/CFO, 10b5-1 Plan